Table 2.

Neutralization phenotype of VC10042 pseudotyped env clones with autologous plasma and with monoclonal antibodies that target the CD4-BS [as well as IgG(2)-CD4]

ypia	Envelope clone	TZM-bl neutralization assay IC50b with the following:
		Plasma (dilution−1)		MAb (μg/ml)
				NIH45-46G54W	b12	VRC01	HAAD antibodies						IgG(2)-CD4	Anticore antibodies
		19y	22y				12A12	12A21	3BNC55	3BNC117	1NC9	1B2530		1-74	4-277	4-252	4-77	1-752
19	VC10042.y19.72	—	102	7.19	—	—	—	—	—	—	—	—	1.35	—	—	—	—	—
	VC10042.y19.101	—	144	7.9	—	—	—	—	—	—	—	—	1.5	—	—	—	—	—
	VC10042.y19.113	25	251	5.22	—	—	—	—	—	—	—	—	>0.03	—	—	—	—	—
	VC10042.y19.205	—	154	5.62	—	—	—	—	—	—	—	—	1.09	—	—	—	—	—
22	VC10042.y22.01	39	58	3.55	—	—	—	—	—	—	—	—	0.15	—	—	—	—	—
	VC10042.y22.02	—	—	—	—	—	—	—	—	—	—	—	0.22	—	—	—	—	—
	VC10042.y22.03	32	35	3.02	—	—	15.6	—	—	2.82	—	—	3.52	—	—	—	—	—
	VC10042.y22.04	—	—	—	—	—	—	—	—	—	—	—	0.28	—	—	—	—	—
	VC10042.y22.05	—	20	—	—	—	—	—	—	—	—	—	0.18	—	—	—	—	—
	VC10042.y22.06	46	31	12.2	—	—	—	—	—	—	—	—	1.59	—	—	—	—	—
	VC10042.y22.07	—	—	—	—	—	—	—	—	—	—	—	0.31	—	—	—	—	—
	VC10042.y22.08	>2,560	>2,560	3.21	0.11	0.018	—	—	—	—	—	—	<0.03	—	—	—	—	—
	VC10042.y22.e1	34	35	4.64	0.32	0.026	—	—	—	—	—	—	0.33	—	<0.2	<0.2	<0.2	<0.2

^aClones were isolated from plasma collected at the indicated year postinfection.

^bThe values reported are the IC₅₀, i.e., the antibody concentration (μg/ml) or plasma dilution at which viral entry is inhibited by 50%. HAAD, highly active agonistic anti-CD4-BS antibody and dependent on the D368R mutation. Anticore, recognizing elements of the CD4-BS but not affected by the D368R mutations. —, no neutralizing activity was observed.